Begelomab (Begedina, ADIENNE Pharma & Biotech), an immunoglobulin G2b monoclonal antibody against CD26, was more effective than currently available agents in treating steroid-refractory acute graft-versus-host disease (GvHD), according to new findings presented at the 2016 annual meeting of the American Society of Hematology (abstract 671).
The results come from two prospective trials conducted by researchers in Italy and the United States. They administered begelomab in 28 patients with